Innovation in Cancer Treatment at Clinic Barcelona Comprehensive Cancer Center
Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, shared a post on LinkedIn:
“Innovation in Cancer Treatment at Clinic Barcelona Comprehensive Cancer Center.
We are proud to share the groundbreaking work led by Sonia Guedan, Alvaro Urbano and their teams on the development of a dual CAR-T therapy against non-Hodgkin lymphoma (NHL).
These advancements are based on our academic anti-CD19 (ARI0001) and anti-BCMA (ARI0002h) CAR-T cells, paving the way for enhanced therapeutic strategies in oncology.
Excitingly, a first-in-human phase 1 clinical trial (CARTD-BG-01; registered at ClinicalTrials.gov [NCT06097455]) has been initiated to evaluate the safety and efficacy of this dual CAR-T therapy, ARI0003, in patients with NHL. This marks an important milestone in translating groundbreaking science into real-world solutions for patients.
This achievement reflects the unwavering commitment of our institution to advancing precision medicine and transforming the future of cancer care.
A heartfelt thank you to Sonia and everyone involved at Campus Clínic Barcelona! Let’s continue innovating, together.
Let’s continue innovating, together.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023